Although higher doses of IFN-α demonstrate greater anti-tumor activity, its significant systemic toxicities result in a very narrow therapeutic index (low maximum tolerated dose vs high optimal therapeutic dose). The gene discussed is IFNA17; the disease is neoplasm.